At the 41st J.P. Morgan Healthcare Conference, Merck CEO Robert M. Davis outlined the company’s growth strategy that banks on the continued expansion of Keytruda and other oncology assets, as well as growth for its human papilloma virus vaccine, Gardasil. Key highlights from Merck’s presentation are:
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,